Cme (CME) Net Income towards Common Stockholders (2009 - 2026)

Cme (CME) has reported Net Income towards Common Stockholders for 18 consecutive years, with $1.0 billion the latest figure, recorded in Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders rose 2.92% year-over-year to $1.0 billion; the TTM figure through Jun 2026 stood at $4.3 billion (up 14.86% YoY), while the FY2025 annual figure was $4.0 billion, up 15.5% from the prior year.
• Net Income towards Common Stockholders declined to $1.0 billion in Q2 2026 per CME's latest filing, from $1.2 billion in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.2 billion in Q4 2025 and bottomed at $630.0 million in Q4 2022.
• Historically, Net Income towards Common Stockholders has averaged $864.2 million across 5 years, with a median of $867.9 million in 2024.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders retreated 27.57% — and 2025, when it soared 35.23%.
• Cme's Net Income towards Common Stockholders stood at $630.0 million in 2022, then climbed by 27.67% to $804.3 million in 2023, then grew by 7.39% to $863.7 million in 2024, then jumped by 35.23% to $1.2 billion in 2025, then decreased by 10.8% to $1.0 billion in 2026.
• Business Quant data shows CME's Net Income towards Common Stockholders at $1.0 billion in Q2 2026, $1.2 billion in Q1 2026, and $1.2 billion in Q4 2025.